Compare · MRNA vs TWST
MRNA vs TWST
Side-by-side comparison of Moderna Inc. (MRNA) and Twist Bioscience Corporation (TWST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and TWST operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $18.22B, about 5.1x TWST ($3.58B).
- Over the past year, MRNA is up 70.1% and TWST is up 54.9% - MRNA leads by 15.3 points.
- Both names hit the wire about 8 times in the past 4 weeks.
- MRNA has more recent analyst coverage (25 ratings vs 12 for TWST).
- Company
- Moderna Inc.
- Twist Bioscience Corporation
- Price
- $45.90+0.40%
- $58.38+2.91%
- Market cap
- $18.22B
- $3.58B
- 1M return
- -9.68%
- +22.78%
- 1Y return
- +70.13%
- +54.85%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2018
- News (4w)
- 8
- 8
- Recent ratings
- 25
- 12
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Latest MRNA
- Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
- Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
- Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
- Moderna to Present at Upcoming Conferences in May 2026
- Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting
- Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
- Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
- SEC Form 4 filed by Mock James M
- Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.
- SEC Form DEF 14A filed by Moderna Inc.
Latest TWST
- Director Starovasnik Melissa A. sold $30,915 worth of shares (500 units at $61.83) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 25,222 units (SEC Form 4)
- President and COO Finn Patrick John sold $141,026 worth of shares (2,321 units at $60.76), decreasing direct ownership by 0.82% to 281,808 units (SEC Form 4) to cover withholding tax
- Chief Executive Officer Leproust Emily M. exercised 9,671 shares at a strike of $8.82 and sold $630,957 worth of shares (9,671 units at $65.24) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 4 filed by Laponis Adam
- Twist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026
- SEC Form 4 filed by Laponis Adam
- SEC Form 4 filed by Laponis Adam
- SEC Form 144 filed by Twist Bioscience Corporation
- SEC Form 4 filed by Starovasnik Melissa A.
- Amendment: SEC Form SCHEDULE 13G/A filed by Twist Bioscience Corporation